Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

During the previous two years, 175 institutional investors and hedge funds held shares of Replimune Group. The most heavily invested institutionals were Baker BROS. Advisors LP ($121.06M), Price T ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

JavaScript is a crucial web component and a building block for many web apps and websites. Sometimes users can accidentally disable JavaScript, but the browser settings can help you enable it again.

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune shares fell 54.2% in three months after the FDA issued a CRL against its RP1 BLA in July. The FDA cited shortcomings in the IGNYTE study data but noted no safety concerns with RP1. Replimune ...